---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLITUDE"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLITUDE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 77 evidence topics quoted from 27 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/amplitude"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLITUDE

<a id="heading-3.1.1"></a>

## 3.1.1 AMPLITUDE

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.1-2"></a>

#### Main objective in the EU Clinical Trials Information System record

> “Main objective Evaluate efficacy and safety of VX-147 in subjects with AMKD”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.1-3"></a>

#### Scope and secondary objectives of Part A and Part B in the EU register record

> “Scope: Efficacy, Safety, Pharmacokinetic”
> “To evaluate the safety and tolerability of VX-147”
> “To identify the optimal dose from Phase 2 to carry forward to Phase 3”
> “To characterize the plasma pharmacokinetics (PK) of VX-147”
> “To evaluate the acceptability of VX-147 in pediatric subjects”
> “Part B: To evaluate changes in proteinuria and kidney function after long-term VX-147 treatment in adult and pediatric subjects”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.1-4"></a>

#### Aim of the trial stated by the company

> “AMPLITUDE is a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.1-5"></a>

#### Aim of the trial stated in the design abstract

> “This Ph2/3 adaptive trial will determine the efficacy and safety of IXP in preserving kidney function and reducing proteinuria in a broad population with AMKD.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-03-30”
> “Primary Completion (Estimated) 2028-06-02”
> “Study Completion (Estimated) 2030-05-07”
> “First Posted 2022-04-06”
> “Last Update Posted 2026-10-26”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 314 locations”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-3"></a>

#### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Alabama Locations”; “Arizona Locations”; “Arkansas Locations”; “California Locations”; “Connecticut Locations”; “District of Columbia Locations”; “Florida Locations”; “Georgia Locations”; “Illinois Locations”; “Indiana Locations”; “Iowa Locations”; “Kansas Locations”; “Louisiana Locations”; “Maryland Locations”; “Massachusetts Locations”; “Michigan Locations”; “Minnesota Locations”; “Mississippi Locations”; “Missouri Locations”; “Nevada Locations”; “New Jersey Locations”; “New Mexico Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Pennsylvania Locations”; “Rhode Island Locations”; “South Carolina Locations”; “Tennessee Locations”; “Texas Locations”; “Virginia Locations”; “Washington Locations”; “Wisconsin Locations” |
| Belgium | “Brussels, Belgium”; “Leuven, Belgium” |
| Brazil | “Aracaju, Brazil”; “Belo Horizonte, Brazil”; “Botucatu, Brazil”; “Campinas, Brazil”; “Curitiba, Brazil”; “Fortaleza, Brazil”; “Goiânia, Brazil”; “Juiz de Fora, Brazil”; “Marília, Brazil”; “Monte Alegre, Brazil”; “Porto Alegre, Brazil”; “Recife, Brazil”; “Rio de Janeiro, Brazil”; “Salvador, Brazil”; “Santo André, Brazil”; “São José do Rio Preto, Brazil”; “São Paulo, Brazil” |
| Canada | “Montreal, Canada”; “Toronto, Canada” |
| Colombia | “Atlántico, Colombia”; “Bogotá, Colombia”; “Cali, Colombia”; “Cartagena, Colombia”; “Ibague, Colombia”; “Medellín, Colombia” |
| France | “Créteil, France”; “Grenoble, France”; “Le Kremlin-Bicêtre, France”; “Limoges, France”; “Marseille, France”; “Paris, France”; “Pointe à Pitre, France”; “Saint-Ouen, France”; “Toulouse, France” |
| Ghana | “Accra, Ghana”; “Cantonments, Ghana”; “Kumasi, Ghana” |
| Netherlands | “Amsterdam, Netherlands” |
| Nigeria | “Enugu, Nigeria”; “Ibadan, Nigeria”; “Idi-Araba, Nigeria”; “Ikeja, Nigeria”; “Lagos, Nigeria” |
| Portugal | “Amadora, Portugal”; “Lisbon, Portugal”; “Loures, Portugal” |
| Puerto Rico | “Mayagüez, Puerto Rico, 06680”; “Rio Piedras, Puerto Rico, 00935”; “San Juan, Puerto Rico, 00917” |
| Spain | “Barcelona, Spain”; “Córdoba, Spain”; “Madrid, Spain”; “Seville, Spain” |
| United Kingdom | “Basildon, United Kingdom”; “Bellshill, United Kingdom”; “Birmingham, United Kingdom”; “Carshalton, United Kingdom”; “Leicester, United Kingdom”; “London, United Kingdom”; “Manchester, United Kingdom”; “Nottingham, United Kingdom” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-4"></a>

#### EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record

> “Locations Belgium, France”
> “Start of trial 25/10/2022”
> “Estimated recruitment start date in EU/EEA: 29/03/2022”
> “Estimated end of trial date in EU/EEA: 31/05/2028”
> “Estimated global end date of the trial: 31/05/2028”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.2-5"></a>

#### Recruitment end in the EU member states

> “Belgium: Ongoing, recruitment ended. Planned participants: 2”
> “France: Ongoing, recruitment ended. Planned participants: 40”
> “15 Sept 2026 Recruitment ended Belgium, France”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.2-6"></a>

#### First authorization and status by country in the earlier EU Clinical Trials Register record

> “First authorisation by a national competent authority 7 Jun 2022”
> “Transitioned to the EU register: Belgium”
> “Ongoing: Spain”
> “Completed: Netherlands”
> “Prematurely ended: Portugal”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.2-7"></a>

#### Trial start year stated by the company

> “We initiated pivotal development of inaxaplin in a single Phase 2/3 adaptive clinical trial”
> “in people with AMKD in 2022.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-3.1.1.2-8"></a>

#### Number of open sites stated by the company in 2023 and 2024

> “Enrollment in the study is ongoing, with more than 100 sites open in the U.S. and internationally, with 250 planned sites in total globally.”

Source: [Vertex Pharmaceuticals press release, NEJM publication (2023)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-publication-new-england-journal-medicine)

> “Enrollment in the study is ongoing, with more than 200 sites open in the U.S. and internationally.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-3.1.1.2-9"></a>

#### Countries in the phase 3 portion stated in the design abstract

> “Phase 3 is ongoing in nine countries, including Belgium and France in Europe.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-2"></a>

#### Design details in the ClinicalTrials.gov record

> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Sequential Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-3"></a>

#### Integrated phase 2 and phase 3 trial in the EU Clinical Trials Information System record

> “Trial Phase Phase II and Phase III (Integrated)”
> “Transition trial Yes”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.3-4"></a>

#### Single pivotal adaptive trial with a phase 2 dose-selection portion

> “The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD.”
> “This randomized, double-blind, placebo-controlled Phase 2/3 adaptive study will first evaluate two doses of VX-147 for 12 weeks to select a dose for Phase 3 and subsequently evaluate the efficacy and safety of the single, selected dose in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.3-5"></a>

#### Phase 2 portion: two doses or placebo for 12 weeks

> “participants will be randomized to receive 1 of 2 daily doses of IXP or placebo for 12wks.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-3.1.1.3-6"></a>

#### Dose selection for phase 3 by the independent data monitoring committee

> “An Independent Data Monitoring Committee (IDMC) reviewed blinded and unblinded Phase 2 safety and efficacy data from the Phase 2/3 pivotal trial, which evaluated two different doses of inaxaplin compared to placebo for 12 weeks of treatment in patients ages 18 to 65 years and recommended the selection of a single inaxaplin dose of 45 mg once daily in the Phase 3 portion of the Phase 2/3 study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “In the AMPLITUDE trial, we selected a 45 mg inaxaplin once daily dose for Phase 3 after the Phase 2 efficacy/safety data had been reviewed by an independent data monitoring committee.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.3-7"></a>

#### Pediatric cohort: adolescents aged 10 to 17 years added to the phase 3 portion

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”
> “The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-3.1.1.3-8"></a>

#### Pre-planned interim analysis at week 48 in a pre-specified number of participants

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.3-9"></a>

#### Part B open-label extension: 96 additional weeks of inaxaplin

> “Experimental: Part B (Phase 3): VX-147”
> “Participants who complete Part A will receive VX-147 for an additional 96 weeks.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-10"></a>

#### Final analysis triggered by follow-up duration and number of composite outcomes

> “The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.3-11"></a>

#### Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror

> “Drug regulated by the U.S. FDA; Data monitoring committee”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

Additional sources: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “Proteinuric kidney disease”
> “Completion of Treatment Period in Part A and no permanent discontinuation of study drug.”
> “Solid organ or bone marrow transplant”
> “Uncontrolled hypertension”
> “History of diabetes mellitus”
> “Known underlying cause of kidney disease including but not limited to sickle cell disease”
> “ESKD (End Stage Kidney Disease) as defined in the protocol.”
> “Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.4-2"></a>

#### Ages and sexes eligible in the ClinicalTrials.gov record

> “10 Years to 65 Years”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.4-3"></a>

#### Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record

> “Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.”
> “For Phase 2, subjects must be between the ages of 18 and 65 years at time of signing first ICF, inclusive. For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.”
> “Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.”
> “Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.”
> “A BMI of 18 to 45 kg/m2, inclusive, and a total body weight ≥40 kg.”
> “A UPCR of ≥0.7 g/g to <10 g/g in the first morning void based on the average of 3 measurements collected on 3 separate days within a 7-day period, during the Screening Period.”
> “Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-4"></a>

#### Part A inclusion criteria: stable background therapy in the EU register record

> “On a stable, maximum tolerated labeled dose (at least 4 weeks before screening) of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), but not both concomitantly, unless documented to be intolerant to ACE inhibitor/ARB.”
> “Subjects taking sodium glucose co transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist (GLP 1a), mineralocorticoid receptor antagonists (MRAs), endothelin antagonists, sparsentan, or permitted immunosuppressants (prednisone ≤10 mg or steroid equivalent, mycophenolate, tacrolimus, cyclosporine, or azathioprine) must have been on a stable dose for 4 weeks before screening.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-5"></a>

#### Part A exclusion criteria in the EU register record

> “Evidence of FSGS with a known cause other than due to APOL1 mutations.”
> “History of diabetes mellitus. A diagnosis of prediabetes is permitted.”
> “Known underlying cause of kidney disease”
> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”
> “Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) RNA, or positive HIV test”
> “Screening blood pressure, based on the average of 3 measurements, of ≥180 mm Hg (systolic) or ≥100 mm Hg (diastolic).”
> “Pregnant or nursing female subjects.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-6"></a>

#### Part B inclusion and exclusion criteria in the EU register record

> “Subject did not withdraw consent during Part A of the study.”
> “ESKD as defined in Section 9.10.1, in Part A.”
> “Ongoing or planned participation in another interventional, therapeutic clinical trial other than Part A of the study.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-7"></a>

#### Eligibility summarized in the 2025 design abstract

> “Our Phase 2/3, randomized, double-blind, placebo-controlled, adaptive trial is enrolling persons without diabetes (Phase 2: 18 to 65 years; Phase 3: 10 to 65 years) with 2 APOL1 variants, UPCR ≥0.7 to <10 g/g, and eGFR ≥25 to <75 mL/min/1.73 m2.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.4-8"></a>

#### Original eligibility at trial start: ages 18 to 60 years

> “Patients aged 18 to 60 years, with two APOL1 mutations, urine protein to creatinine ratio (UPCR) ≥0.7 g/g to <10 g/g, eGFR ≥25 to <75 mL/min/1.73m2 and on stable doses of standard of care medications are eligible to enroll.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.4-9"></a>

#### Population described by the company: severe proteinuria and no comorbidities causing kidney disease

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The phase 2/3 randomized, placebo-controlled AMPLITUDE trial is evaluating the effects of IXP on preserving kidney function and reducing proteinuria in non-diabetic persons with AMKD and severe proteinuria (UPCR ≥0.7 to <10g/g).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Description | Intervention |
| --- | --- | --- |
| Part A, inaxaplin | “Experimental: Part A (Phase 2/3): VX-147”; “Participants will be randomized to receive different doses of VX-147. Participants will receive the selected dose of VX-147 for atleast 96 weeks.” | “Drug: VX-147”; “Tablets for oral administration.” |
| Part A, placebo | “Placebo Comparator: Part A (Phase 2/3): Placebo”; “Participants will receive placebo matched to VX-147.” | “Drug: Placebo”; “Tablets for oral administration.” |
| Part B, inaxaplin | “Experimental: Part B (Phase 3): VX-147”; “Participants who complete Part A will receive VX-147 for an additional 96 weeks.” | “Drug: VX-147”; “Tablets for oral administration.” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.5-2"></a>

#### Phase 3 dose: inaxaplin 45 mg once daily or placebo added to standard of care

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.5-3"></a>

#### Investigational medicinal product and placebo in the EU register record

| Field | Quoted record |
| --- | --- |
| Test product | “VX-147 film-coated tablet” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Orphan designation number | “EMA/OD/0000090156” |
| Placebo | “VX-147, Coated Placebo Tablet” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.5-4"></a>

#### Phase 2 portion: two inaxaplin doses or placebo for 12 weeks

> “In the Phase 2 component, participants received inaxaplin (different doses) or placebo for 12 weeks to select a dose for evaluation of inaxaplin efficacy/safety in ∼400 participants in Phase 3.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Percent Change in UPCR at Week 48 and eGFR Slope as the Primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

##### Registered primary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)” | “From Baseline to Week 48” |
| “Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim Analysis” | “From Baseline Through >= Week 48” |
| “Part A: eGFR Slope Assessed at Final Analysis” | “From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)” |
| “Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.6.1-2"></a>

##### Registered secondary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)” |
| “Part A: Maximum Plasma Concentration (Cmax) of VX-147” | “Day 1 and Week 40” |
| “Part A: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-147” | “Day 1 and Week 40” |
| “Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-147” | “Day 1 up to Week 40” |
| “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4” | “Day 1 and Week 48” |
| “Part B: Percent Change From Baseline in UPCR Over Time” | “From Baseline Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |
| “Part B: eGFR Slope Assessment” | “Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.6.1-3"></a>

##### Primary and secondary end points in the EU register record

> “Part A: Percent change in UPCR evaluated from baseline at Week 48 (assessed at the IA)”
> “eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”
> “Part B: Safety and tolerability assessments based on AEs, clinical laboratory values, and vital signs”
> “Part A: Acceptability of tablet formulation of VX-147 in pediatric subjects using the convenience domain of the Treatment Satisfaction Questionnaire for Medication (TSQM)”
> “Part B: Percent change in UPCR from baseline over time”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.6.1-4"></a>

##### Final analysis: eGFR slope primary endpoint and composite clinical outcome secondary endpoint

> “The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the inaxaplin selected dose compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in eGFR, the onset of end-stage kidney disease (i.e., maintenance dialysis for ≥28 days, kidney transplantation, or a sustained eGFR of <15 mL/min/1.73 m2), or death.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="topic-3.1.1.6.1-5"></a>

##### Interim analysis endpoints as first described: eGFR slope supported by proteinuria

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope in VX-147 versus placebo, supported by a percent change from baseline in proteinuria. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.6.1-6"></a>

##### Interim analysis endpoints in the design abstract: UPCR and eGFR slope

> “The trial has a pre-planned interim analysis at Week 48 evaluating proteinuria, as measured by the percent change from baseline in UPCR, and eGFR slope.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-3.1.1.6.1-7"></a>

##### Discussions with the FDA on the accelerated approval pathway

> “We are very pleased to have concluded our discussions with the FDA, enabling us to initiate the pivotal development program evaluating VX-147 in the broad patient population with AMKD and to have a clear path forward for potential accelerated approval in the U.S.”
> “The primary endpoint of this study is reduction in the rate of decline of kidney function as measured by estimated glomerular filtration rate (eGFR) slope versus placebo at approximately two years.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.6.1-8"></a>

##### Interim analysis as the basis for an accelerated approval application

> “If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.6.1-9"></a>

##### GFR slope as a surrogate endpoint: individual participant data meta-analysis of 66 studies

> “Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.”
> “The slope of the meta-regression line is −0.35 (95% BCI −0.42 to −0.29) per mL/min per 1.73 m2/year), indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%).”

Source: [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/)

<a id="topic-3.1.1.6.1-10"></a>

##### Albuminuria and GFR slope as end points: NKF workshop with the FDA and EMA

> “The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions.”
> “We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.”

Source: [Levey et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31473020/)

<a id="topic-3.1.1.6.1-11"></a>

##### GFR slope qualified by the EMA as a validated surrogate endpoint when clinical endpoints are not feasible

> “The proposed novel method, GFR slope, is qualified to be used as a validated surrogate endpoint for CKD progression in randomised controlled clinical trials to support marketing authorisation and extension of indication approvals when the use of clinical endpoints is not feasible due to rarity of the disease or need for a very long study period.”
> “An estimate of the treatment effect on GFR slope should be based on a sufficiently long-term evaluation period within a trial, preferably 3 years and usually at least 2 years.”

Source: [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf)

<a id="topic-3.1.1.6.1-12"></a>

##### Proteinuria reduction as a reasonably likely surrogate end point for accelerated approval: Kidney Health Initiative

> “In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.”

Source: [Thompson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419287/)

<a id="topic-3.1.1.6.1-13"></a>

##### Proteinuria as an endpoint in focal segmental glomerulosclerosis: Kidney Health Initiative

> “Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

<a id="topic-3.1.1.6.1-14"></a>

##### Proteinuria reduction and kidney survival in steroid-resistant focal segmental glomerulosclerosis

> “A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).”
> “There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).”

Source: [Troost et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854818/)

<a id="topic-3.1.1.6.1-15"></a>

##### Albuminuria change as a surrogate endpoint across 48 randomized trials

> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-3.1.1.6.1-16"></a>

##### Albuminuria change as a surrogate endpoint in APOL1-mediated kidney disease: real-world cohort preprint

> “However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”
> “Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.1.6.1-17"></a>

##### Regulatory precedent in focal segmental glomerulosclerosis: FDA approval to reduce proteinuria

> “Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.”

Source: [Travere Therapeutics press release, FILSPARI FSGS approval (2026)](https://www.businesswire.com/news/home/20260413839195/en/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment in the phase 2 and phase 3 portions

> “Approximately 66 patients are planned to be enrolled in the Phase 2 dose-ranging portion of the study, and approximately 400 additional patients are planned to be enrolled in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="topic-3.1.1.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 522”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned participants in the EU member states

> “Belgium: Ongoing, recruitment ended. Planned participants: 2”
> “France: Ongoing, recruitment ended. Planned participants: 40”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants dosed in the phase 2 portion

> “Among 64 participants dosed, 34 (53.1%), 24 (37.5%), and 6 (9.4%) have G1/G1, G1/G2, or G2/G2 genotypes, respectively.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.7.1-5"></a>

##### Interim analysis cohort: a pre-specified number of participants at week 48

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.7.1-6"></a>

##### Number of composite clinical outcomes required for the final analysis

> “The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Interim analysis after the interim analysis cohort reaches 48 weeks of treatment

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-3.1.1.7.2-2"></a>

##### Interim analysis cohort limited to participants with primary AMKD

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-3.1.1.7.2-3"></a>

##### Duration of eGFR data at the interim and final analyses

> “eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.7.2-4"></a>

##### Final analysis timing in the design abstract

> “Final analysis will occur when ≥2 years of eGFR data and ∼187 composite clinical outcomes are obtained.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### APOL1 genotyping study used to identify candidates: interim analysis

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR ≥0.5 g/g.”
> “The genotyping study interim analysis included 2866 participants of whom 674 (23.5%) have 2 APOL1 variants; 164 of the 674 (24.3%) participants are from Europe. Of the 674 participants with 2 APOL1 variants in this study, 36 enrolled in the completed Phase 2 component of AMPLITUDE.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.8.1-2"></a>

##### Completion of enrollment in the phase 2 dose-ranging portion

> “Completed enrollment in the Phase 2B dose-ranging portion of the study of inaxaplin for the treatment of patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming)

<a id="topic-3.1.1.8.1-3"></a>

##### Completion of enrollment in the interim analysis cohort in September 2025

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-3.1.1.8.1-4"></a>

##### Completion of full enrollment in 2026

> “Having completed enrollment in the interim analysis (IA) cohort of the AMPLITUDE pivotal study last year, Vertex has now completed full enrollment.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “We have completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

<a id="topic-3.1.1.8.1-5"></a>

##### Enrollment and recruitment status in the ClinicalTrials.gov record

> “Enrollment (Actual) 522”
> “No longer looking for participants”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Phase 2 portion: APOL1 genotype, age, and eGFR of 64 dosed participants

> “Among 64 participants dosed, 34 (53.1%), 24 (37.5%), and 6 (9.4%) have G1/G1, G1/G2, or G2/G2 genotypes, respectively. The mean (SD) age was 42.7 (11.0) years and mean (SD) baseline eGFR was 42.8 (14.0) mL/min/1.73 m2.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

Additional sources: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Interim analysis results not yet reported

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-3.1.1.8.3-2"></a>

##### No results posted in the registry

> “Summary of the results: not applicable: the trial has not ended.”
> “Other registries: ClinicalTrials.gov NCT05312879: no results posted.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: study limitations

As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879); [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00); [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy); [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477); [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf); [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.1.9-2"></a>

#### Populations not studied in AMPLITUDE

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “populations not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.9-3"></a>

#### Surrogacy of GFR slope in rare diseases may need support from additional endpoints

> “For rare diseases and disease entities with less weight in the trial-level surrogacy analysis, considerations may differ, and support of efficacy may need to be provided by additional endpoints and/or demonstration of lack of a detrimental effect.”
> “In the presence of large acute effects, GFR slope might not be suitable as a surrogate endpoint.”

Source: [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf)

<a id="topic-3.1.1.9-4"></a>

#### Accelerated approval requires verification of clinical benefit

> “the FDA has generally required post-marketing studies to verify and describe the clinical benefit of products approved under the accelerated approval pathway”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
